Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

648
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
648
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.5K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

724
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
724
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality evaluation of randomized controlled trials of antipsychotic drugs for schizophrenia published in Chinese journals.

Schizophrenia research·2026
Same author

Cochrane Evaluation of (Semi-) Automated Review Methods (CESAR): Protocol for an adaptive platform study within reviews.

Journal of clinical epidemiology·2026
Same author

Improving research quality of psychological interventions in evidence-based medicine.

The lancet. Psychiatry·2026
Same author

Synthesis of pyrazolo[5,1-<i>a</i>]isoindoles <i>via</i> silver-mediated cascade cyclization of 1,5-enynes with diazo compounds.

Chemical communications (Cambridge, England)·2026
Same author

Regional homogeneity and interhemispheric connectivity alterations in major depressive disorder.

Asian journal of psychiatry·2026
Same author

Operation Stork Speed represents an opportunity to reform infant formula clinical trials.

Nature food·2026
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Mar 11, 2026

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice
04:44

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice

Published on: February 16, 2024

2.3K

Valproate for schizophrenia.

Yijun Wang1, Jun Xia, Bartosz Helfer

  • 1Neuro-Cognitive Psychology Master Program, Ludwig-Maximilians-Universität München, Thalkirchner Str. 9, Munich, Bavaria, Germany, D-80337.

The Cochrane Database of Systematic Reviews
|November 25, 2016
PubMed
Summary
This summary is machine-generated.

Valproate augmentation for schizophrenia shows limited evidence for improved clinical response and reduced aggression, but is associated with increased sedation. Further blinded studies are needed to confirm efficacy and safety in schizophrenia treatment.

More Related Videos

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.7K
Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K

Related Experiment Videos

Last Updated: Mar 11, 2026

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice
04:44

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice

Published on: February 16, 2024

2.3K
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.7K
Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Trials

Background:

  • Many individuals with schizophrenia exhibit inadequate response to standard antipsychotic treatments.
  • Valproate is explored as an adjunctive therapy for treatment-resistant schizophrenia and schizoaffective disorders.

Purpose of the Study:

  • To evaluate valproate as monotherapy for schizophrenia and schizoaffective psychoses.
  • To assess the efficacy of valproate augmentation to antipsychotic medications in these conditions.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) identified through comprehensive database searches and industry contact.
  • Included trials compared valproate (alone or as adjunct) against antipsychotics or placebo.
  • Data extraction and risk of bias assessment were performed independently by at least two authors.

Main Results:

  • Valproate augmentation showed a potential increase in clinical response (low-quality evidence), but this finding was sensitive to study design.
  • No significant difference in treatment acceptability or overall tolerability was observed between valproate and placebo.
  • Valproate was associated with reduced aggression (very low-quality evidence) but increased sedation (low-quality evidence).

Conclusions:

  • Limited evidence suggests valproate augmentation may improve clinical response and reduce aggression in schizophrenia, primarily from open-label trials.
  • Valproate use was linked to increased sedation and dizziness.
  • High-quality, blinded randomized controlled trials are necessary to establish clear recommendations, particularly for aggressive or treatment-resistant schizophrenia and schizoaffective disorders.